Arun Sanyal, M.D., director of the VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, discusses the ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Though popular weight loss jabs like Ozempic and Wegovy have been deemed safe and effective by the FDA, concerning side ...

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with ...

A new study analyzed how often people develop severe side effects after taking semaglutide — known by brand names Ozempic and ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new study published Wednesday.

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

A decision is expected in the fourth quarter of 2025.

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...